Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives $64.44 Consensus PT from Analysts

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) have been assigned a consensus rating of “Buy” from the eleven analysts that are presently covering the stock, MarketBeat reports. Eleven analysts have rated the stock with a buy rating. The average 1-year price target among analysts that have covered the stock in the last year is $64.44.

A number of equities analysts have commented on JSPR shares. BMO Capital Markets started coverage on shares of Jasper Therapeutics in a research note on Friday, December 6th. They issued an “outperform” rating and a $63.00 price objective for the company. JMP Securities reissued a “market outperform” rating and issued a $70.00 price objective on shares of Jasper Therapeutics in a research note on Monday, January 6th. HC Wainwright dropped their price objective on shares of Jasper Therapeutics from $60.00 to $40.00 and set a “buy” rating for the company in a research note on Friday, January 10th. Royal Bank of Canada dropped their price target on shares of Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating for the company in a research note on Thursday, January 9th. Finally, UBS Group began coverage on shares of Jasper Therapeutics in a research note on Thursday, February 13th. They set a “buy” rating and a $38.00 price target for the company.

Jasper Therapeutics Stock Down 3.1 %

Shares of NASDAQ:JSPR opened at $5.97 on Thursday. Jasper Therapeutics has a 52 week low of $4.55 and a 52 week high of $31.01. The stock has a market capitalization of $89.52 million, a P/E ratio of -1.26 and a beta of 2.11. The firm has a fifty day simple moving average of $11.23 and a two-hundred day simple moving average of $17.13.

Institutional Trading of Jasper Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Soleus Capital Management L.P. raised its position in Jasper Therapeutics by 11.2% during the fourth quarter. Soleus Capital Management L.P. now owns 1,494,420 shares of the company’s stock worth $31,951,000 after acquiring an additional 150,755 shares during the period. Braidwell LP raised its position in Jasper Therapeutics by 47.9% during the fourth quarter. Braidwell LP now owns 714,658 shares of the company’s stock worth $15,279,000 after acquiring an additional 231,358 shares during the period. Integral Health Asset Management LLC raised its position in Jasper Therapeutics by 85.7% during the fourth quarter. Integral Health Asset Management LLC now owns 650,000 shares of the company’s stock worth $13,897,000 after acquiring an additional 300,000 shares during the period. Samsara BioCapital LLC raised its position in Jasper Therapeutics by 11.4% during the third quarter. Samsara BioCapital LLC now owns 584,642 shares of the company’s stock worth $10,997,000 after acquiring an additional 59,642 shares during the period. Finally, Rock Springs Capital Management LP raised its position in Jasper Therapeutics by 0.9% during the fourth quarter. Rock Springs Capital Management LP now owns 463,088 shares of the company’s stock worth $9,901,000 after acquiring an additional 4,000 shares during the period. 79.85% of the stock is owned by hedge funds and other institutional investors.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.